Protein Degraders Progress Limitations Future Directions pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
In this behind-the-scenes interview, we speak to Dr. Sinead Knight, chair of SLAS Europe 2023, about this years programme, highlighting the key topics and speakers.
Targeted protein degradation uses different types of "degrading" drugs (degraders) to force proximity between a target protein (for example, a mutated protein that contributes to the development of a disease) and the cellular machinery that directs protein degradation.
This week, the Institute for Research in Biomedicine (IRB Barcelona) and the BBVA Foundation are hosting the 39th Barcelona BioMed Conference an event in which leading figures can exchange ideas and discuss the latest advances in the field of proximity induction-based pharmacology. The “Proximity-inducing pharmacology: Targeted protein degradation and beyond” conference, co-organised by Dr. Cristina Mayor-Ruiz, from IRB Barcelona, and Dr. Georg E. Winter, from the CeMM Research Center for Molecular Medicine in Vienna (Austria), is being held in Barcelona between 22 and 24 May. Dr. Mayor-Ruiz and Dr. Winter are experts in the development of "degraders".
CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancerStrong preclinical data generated with CT-02 against NEK7CT-05.